Further, this type of MDM2 inhibitor is challenged with resistance conferred by MDM4 overexpression in cancer cells since MDM4 can bind to and inhibit the p53 transactivation domain in the absence of MDM2 [10,11,12]. Here, TP53 is linked to cancer.